Viking Therapeutics, Inc. (VKTX) Presents at Morgan Stanley twenty third Annual World Healthcare

Michael Ulz
Fairness Analyst

All proper. Good afternoon, everybody, and thanks for becoming a member of us on the Morgan Stanley World Healthcare Convention. I am Mike Ulz, one of many biotech analysts right here, and it is my pleasure to introduce Brian Lian, CEO from Viking Therapeutics. Earlier than we get began, I simply have to learn a fast disclaimer. For necessary disclosures, please see the Morgan Stanley analysis disclosure web site at www.morganstanley.com/researchdisclosures. And when you have any questions, please attain out to your Morgan Stanley gross sales consultant.

And with that, perhaps, Brian, I will simply hand it over to you to make some introductory feedback for those who may not be aware of your story.

Brian Lian
President, CEO & Director

Certain, certain. Thanks, Mike. Because of Morgan Stanley additionally for the invitation. I recognize the schedule and actually a fantastic record of traders to fulfill with. So sure, I am Brian Lian, CEO of Viking. We have now lots happening on the firm. We have now at present, 2 Section III trials ongoing in weight problems. These had been initiated within the second quarter, appear to be enrolling effectively up to now and searching ahead to finishing the enrollment after which executing these research by way of the following 78 weeks of remedy interval following the completion of enrollment.

We lately learn out a Section IIa trial, 13-week research with an oral formulation of the identical compound that is in Section III. This was a 13-week each day dosing research, which confirmed as much as 12% weight reduction at 13 weeks, which we’re actually, actually comfortable about, good tolerability. And the following step with the oral program can be to hopefully schedule an finish of